Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.30 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | PDE1A | P54750 | 1/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.30 |
| ▸ | SLC33A1 | O00400 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9948179 | 0.96 | AGTR1 (0.33) | TNKSTNKS2L3MBTL1 | |
| SCHEMBL16458227 | 0.95 | MAPT (0.33) | TNKSTNKS2L3MBTL1 | |
| SCHEMBL16458623 | 0.94 | TNKS (0.34) | TNKSTNKS2PDE5AGRIN1GRIN2B | |
| SCHEMBL9948538 | 0.93 | AGTR1 (0.33) | TNKSTNKS2PDE5APDE1APDE1B | |
| SCHEMBL9948204 | 0.93 | AGTR1 (0.35) | TNKSTNKS2PDE5APDE1APDE1B | |
| SCHEMBL9948139 | 0.92 | AGTR1 (0.33) | TNKSTNKS2PDE5APPARGPDE1A | |
| SCHEMBL9948455 | 0.90 | APLNR (0.34) | PPARG | |
| SCHEMBL9948502 | 0.87 | APLNR (0.35) | — | |
| SCHEMBL15418045 | 0.86 | KDM5A (0.33) | GRM2PPARGGAAL3MBTL1 | |
| SCHEMBL12526770 | 0.85 | SLC33A1 (0.43) | PPARGSLC33A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315493-B2 | Phenylpyridine derivative and drug containing same | KOWA COMPANY, LTD. (JP) | 2016-04-19 | — | — | US | disclosed |
| US-20140011823-A1 | NOVEL PHENYLPYRIDINE DERIVATIVE AND DRUG CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011823-A1 | NOVEL PHENYLPYRIDINE DERIVATIVE AND DRUG CONTAINING SAME | AGTR2, AGTR1, PPARD | TNKS 4331/4885TNKS2 3412/4885PDE5A 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.